IPSEN S A/S (OTCMKTS:IPSEY) has earned an average rating of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company.
IPSEY has been the topic of a number of research analyst reports. Zacks Investment Research upgraded IPSEN S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, June 10th. JPMorgan Chase & Co. upgraded IPSEN S A/S from an “underweight” rating to a “neutral” rating in a research note on Monday, May 18th. Bank of America upgraded IPSEN S A/S from a “neutral” rating to a “buy” rating in a research note on Monday, June 1st. Barclays restated an “equal weight” rating on shares of IPSEN S A/S in a research note on Monday, June 1st. Finally, ValuEngine upgraded IPSEN S A/S from a “sell” rating to a “hold” rating in a research note on Thursday, July 2nd.
Shares of IPSEY traded up $0.72 during midday trading on Thursday, hitting $21.75. The stock had a trading volume of 1,700 shares, compared to its average volume of 1,114. The firm has a market cap of $7.05 billion, a P/E ratio of 11.51 and a beta of 1.26. IPSEN S A/S has a fifty-two week low of $9.10 and a fifty-two week high of $33.17. The business has a 50-day simple moving average of $20.19 and a two-hundred day simple moving average of $18.34.
IPSEN S A/S Company Profile
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Recommended Story: FTSE 100 Index
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.